In June 2021, the agency approved Wegovy (semaglutide 2.4 mg once weekly) for weight management in adults with a body mass index (BMI) of 30 kg/m or greater (obesity), or a BMI of 27 kg/m or greater (overweight) with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea
Sympathetic nervous system effects may contribute to heart rate changes
5: Youre losing muscle along with fat When weight loss is rapid, the body sheds both fat and muscle
Learn more about making the switch from semaglutide to tirzepatide (but dont make any medication changes without speaking with your healthcare provider)
The hypothalamus, a part of the brain that controls satiety and appetite, is considered to express GLP-1 receptors, which are thought to play a role in weight loss
GLP-1 Activity GLP-1 receptor activation can help reduce appetite, slow gastric emptying, support insulin response, and improve blood sugar regulation